A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine

Lisa Huang
University of Massachusetts Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/anesthesiology_pubs

Part of the Anesthesia and Analgesia Commons, Anesthesiology Commons, Health Services Administration Commons, History of Science, Technology, and Medicine Commons, Nutritional and Metabolic Diseases Commons, and the Pathological Conditions, Signs and Symptoms Commons

Repository Citation

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Anesthesiology and Perioperative Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Accepted Manuscript

A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine

Lisa Huang, Christine N. Sang, Manisha S. Desai

PII: S2352-4529(18)30094-X
Reference: JANH 208
To appear in: Journal of Anesthesia History
Received date: 4 July 2018
Accepted date: 25 July 2018

Please cite this article as: Lisa Huang, Christine N. Sang, Manisha S. Desai, A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine. Janh (2018), doi:10.1016/j.janh.2018.07.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A chronology for the identification and disclosure of adverse effects of succinylcholine

Lisa Huang, B.A.* †
Christine N. Sang, M.D. ‡
Manisha S. Desai, M.D. *§

*University of Massachusetts Medical School, Worcester, Massachusetts
†Medical Student
§Associate Professor of Anesthesiology
‡Associate Professor of Anaesthesia

Harvard Medical School – Brigham and Women’s Hospital, Boston, Massachusetts

This study was supported by intramural funds.

Lisa Huang is a recipient of a Wood Library-Museum of Anesthesiology Fellowship Award

Corresponding Author: Lisa Huang, B.A.
Lisa.Huang@umassmed.edu
University of Massachusetts Medical School, Worcester, Massachusetts
55 Lake Avenue North, Worcester, Massachusetts 01655

Keywords: adverse effects, side effects, succinylcholine
Abstract

Background: New therapies are created to address specific problems and enjoy popularity as they enter widespread clinical use. Broader use can reveal unknown adverse effects and impact the life cycle significantly. Succinylcholine, a depolarizing neuromuscular blocker, was the product of decades of research surrounding the ancient compound, curare. It was introduced into practice in the 1940s by Burroughs Wellcome and Company (BW Co.) and was welcomed due to its rapidly acting muscle relaxation effects. Global clinical use revealed adverse effects, both minor and major, in particular, hyperkalemia and malignant hyperthermia. We investigated when practitioners and the manufacturer became aware of these adverse effects, how information about these side effects were disseminated, and whether the manufacturer met the regulatory requirements of the time, specifically regarding the timely reporting of adverse effects.

Sources: Primary literature search using online and archived documents was conducted at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois. We consulted documents submitted by BW Co. to federal authorities, through the Freedom of Information Act (FOIA), Food and Drug Administration (FDA) reports, promotional advertisements, package inserts, published articles, and textbooks.

Results: Initial clinical testing in humans in 1952 found no adverse effects on cardiovascular or respiratory systems. Fasciculations and myalgia were early side effects described in case reports in 1952. Large-scale clinical trials in 1953 found abnormally long recovery times among some patients; the discovery of abnormal pseudocholinesterase enzyme activity was not fully demonstrated until the early 1960s. Bradycardia was first reported in 1957 in children, and in 1959 in adults. In 1960, animal studies reported a transient increase in plasma potassium; further experiments in 1969 clearly demonstrated succinylcholine-induced hyperkalemia in burn
patients. Malignant hyperthermia was first described in 1966. Similar cases of elevated temperatures and muscle rigidity were described globally but the underlying mechanism was not elucidated until the 1990s. Standard anesthesia textbooks did not report major side effects of succinylcholine until 1960 and included newly documented side effects with each edition. BW Co.'s packaging contained warnings as early as the 1950's but were later updated in 1962 and beyond to reflect the newly discovered hyperkalemia and malignant hyperthermia.

**Conclusion:** Particularly given the regulatory environment of the time, BW Co. appropriately reported the adverse effects of succinylcholine after market entry; it updated promotional and packaging material in a timely manner to reflect newly discovered adverse effects. The toxicity, though alarming and put clinicians on alert, did not seem to heavily impact succinylcholine's use, given its various desirable properties. It is still a choice muscle relaxant used today, although there are efforts to develop superior agents to replace succinylcholine.
Introduction

Pharmacological and nonpharmacological treatments possess a life cycle like that of newly introduced products in our daily lives. The novelty of a new and different drug attracts early adopters who are eager to test out the promised effects, after which there is a general acceptance by clinicians at large. Often, with broader use and off-label use, the adverse effects of the drug appear, with some that are predictable while others are not. Over time, enthusiasm for these drugs may wane as the reality of harmful side effects sets in and as investigators discover replacements with improved safety and efficacy, just as these drugs may have replaced earlier ones. These drugs disappear from the scene permanently when they are no longer commercialized.

We discuss the introduction, evolution of use, identification and publicizing of side effects of a commonly used medication in modern anesthetic practice: succinylcholine, also known as suxamethonium chloride (international nonproprietary name). D-Tubocurarine had been introduced into clinical use in the 1930s and was extremely useful for surgical procedures involving the abdomen. However, its duration of action (30-60 minutes) was too long for short procedures such as electroconvulsive therapy, dental extraction, tracheal intubation, and operations of a short duration. Succinylcholine fulfilled the requirements for the aforementioned short procedures, and continuous infusions were used for longer procedures as well.

As the drug was being developed for clinical use, the manufacturer, Burroughs Wellcome and Company (BW Co.), would have conducted investigations to determine clinical efficacy while also noting adverse effects. We sought to determine if clinically significant adverse reactions may have been evident in retrospect and should have been included in the marketing materials.
The United States Food and Drug Administration (FDA)’s pharmaceutical approval process underwent numerous amendments over its existence. The 1938 Federal Food, Drug, and Cosmetic Act began requiring manufacturers to demonstrate product safety prior to approval for marketing. [1] Specific requirements by the FDA for the disclosure of risk information in advertising materials and promotional labeling were tied to the expansion of its authority. [2] In 1951, Congress passed the Durham Humprey Amendment, which required that specific drugs be prescribed by a medical professional. This was the first time that there was a statutory definition of drugs based on defined criteria. A period followed in which promotional materials were everywhere; interestingly, the FDA did not regulate advertising in medical journals; this was the role of the Federal Trade Commission (FTC; Wheeler Lea Act, 1938). In fact, claims of efficacy were often made despite a lack of evidence. In part because evidence for causality (particularly with low frequency adverse events) is best inferred from large systematic clinical trials that may not have been available at the time, safety was typically assumed. Thus, congressional hearings on pharmaceutical marketing practices ensued, accelerated by an observation in Europe that thalidomide was associated with serious birth defects.

The Federal Trade Commission (FTC) is also granted oversight of advertising for FDA-regulated materials. In the years leading up to the discovery of succinylcholine, the FDA developed more regulations, including guidelines of good manufacturing practices for quality control in 1941, banning illegal drug sales in 1948, clarification of use on drug labels in 1950, and the limitation of sale of drugs meant to be used by medical professionals in the 1951 Durham-Humphrey Amendment. [3] In 1952, a voluntary program to report drug reactions was formed and a decade later, the Kefauver-Harris Amendments were passed in 1962, which not only required manufacturers to prove product efficacy through controlled clinical trials prior to
approval, but also to report any serious side effects after market entry. [4] These amendments also transferred the control of pharmaceutical advertising to the FDA. In the years that followed, the FDA put forth further rules to regulate clinical trials, including the Investigational New Drug and New Drug Application approval pathways; these required manufacturers to demonstrate new agents’ safety through different phases of testing, as well as approval from an Institutional Review Board of information pertaining to the sponsors, methods, and patients involved before the study was allowed to be conducted. [5] The Fair Packaging and Labeling Act of 1966 required all products to have honest and informative labels and the FDA required package inserts with information about risks and benefits for all medications starting in 1970. The development of enhanced safety standards through the 1970s by the FDA formed the backdrop for establishing a legal responsibility and accountability for BW Co. in its production and marketing of succinylcholine. We investigate marketing material and package inserts by BW Co. for succinylcholine over three decades to track the updates in listed side effects.

Sources

Primary literature search was conducted at the Wood Library-Museum of Anesthesiology, Schaumberg, Illinois, using archived documents and online databases. Archived documents consisted of advertisements in early editions of anesthesia journals, physical copies of original research articles, case reports, drug package inserts, drug information packets, and other manufacturer marketing materials. We also reviewed documents submitted to the Federal Drug Administration (FDA) by BW Co. for approval of succinylcholine’s use in the clinical setting (through the Freedom of Information Act) and other FDA reports. We examined updated editions of anesthesia and pharmacology textbooks to ascertain when information about adverse effects
was published in standard medical textbooks, specifically Goodman and Gilman’s *Pharmacological Basis of Therapeutics*, Dripps/Eckenhoff/Vandam’s *Introduction to Anesthesia*, Collins’ *Principles of Anesthesiology*, and Wylie’s *A Practice of Anaesthesia*. We reviewed the textbooks’ sections on neuromuscular blocking agents and adverse effects, specifically, hyperkalemia, and malignant hyperthermia.

**History and Synthesis**

The history of neuromuscular blocking agents can be traced back to curare. This plant extract was used by aboriginal tribes in South America to hunt wild animals for centuries. Its notable paralytic effect on the respiratory system of animals was carried into clinical practice in the 1800s, when curare was used to treat tetanus. In 1856 Claude Bernard conducted detailed laboratory experiments to elucidate the drug’s mechanism and site of action. [6] Attempts were made to purify and then synthesize the compounds that gave curare its properties. This resulted in the isolation of d-tubocurarine by Harold King in 1935. King’s discovery prompted further pharmacological investigation into compounds that mimicked the structure of d-tubocurarine, especially its two separated quaternary groups, which were thought to be responsible for the neuromuscular block. [7]

Three different groups reported the action of succinylcholine at the neuromuscular junction from 1949-1950: one led by Nobel-prize winner Daniel Bovet in Italy, one led by James Walker in the U.K., and one led by Edwin de Beer in the U.S. [8-11] It should be noted that Reid Hunt originally developed succinylcholine in 1906 through his studies of acetylcholine but conducted his experiments of succinylcholine in the presence of curare, and thus succinylcholine’s muscle relaxation properties went unnoticed. [12]
De Beer and Castillo’s report on succinylcholine in the 1950s described its neuromuscular blocking action in animal studies. [8] The compound was tested on cats, dogs, rabbits, mice, and frogs. The authors noted that the paralysis produced was on par with d-tubocurarine’s effects, even with a very low dose succinylcholine, and marveled at its rapid onset and duration of the neuromuscular block. They did not observe any effects on blood pressure. They remarked that the action of succinylcholine could be prolonged by the administration of anticholinesterase inhibitors (such as physostigmine), whereas the action of d-tubocurarine was antagonized and nearly abolished by anticholinesterase inhibitors. These findings were consistent with previous observations by Bovet-Nitti. [8] At the time, Castillo’s and Bovet-Nitti’s teams assumed that the prolongation of action was due to physostigmine antagonizing a downstream enzyme that metabolized succinylcholine. Bovet’s animal studies in 1951 found that large doses of succinylcholine caused transient hypertension. [13]

Succinylcholine was manufactured as an iodized salt, and also as succinylcholine chloride. [14, 15] The iodized salt was water soluble, but would undergo spontaneous breakdown over time, requiring clinicians to either dissolve it immediately prior to use or administer it subsequently without knowing how much active ingredient remained. [16] Moreover, patients allergic to iodinated products and shellfish could receive the chlorinated compound safely. [17] As a result, succinylcholine chloride is the form in which the drug has been manufactured ever since.

**Adverse Effects Publicized**

In 1952, Thesleff’s group in Stockholm reported that an injection of succinylcholine caused fasciculations initially, and these were followed by muscle paralysis in animals.
Fasciculations were fairly common side effect that was reported in nearly every study that described the use of succinylcholine. [14, 18, 19]

Thesleff’s group also reported that doses greater than 2mg/kg caused transient increases in blood pressure in animals. Doses greater than 30mg/kg caused bradycardia or cardiac arrhythmias in animals. [14] Bradycardia wasn’t reported in human subjects until 1957, where it was first described in young children and infants. [20] In 1959, Bullough, commenting on a manuscript published in the previous year by Martin, summarized their findings on adult patients: bradycardia occurred following repeated administrations of succinylcholine, sometimes with leading to arrhythmias or cardiac arrest, recommending premedication with atropine if repeated dosing was required. [21]

Initial clinical testing on over 1,000 patients reported no effects on blood pressure, pulse, or salivation, no bronchospasm, and no histamine liberation. [15, 22, 23] An early description of the safety and efficacy of succinylcholine was reported with self-administration in 1952. The author suggested that the drug was safe and could be used to provide muscle relaxation during abdominal and thoracic operations, facilitate tracheal intubation, overcome laryngospasm, and be used as an adjunct during electroconvulsive therapy. [24] Other case reports in 1952 began to draw attention to abnormally long recovery times in some patients, which contradicted succinylcholine’s characteristic short duration of action. [25, 26] This alarming adverse effect of prolonged apnea was confirmed in large-scale clinical trials in 1953. The explanation proposed at the time was that these patients had lower cholinesterase levels, meaning they were unable to metabolize succinylcholine at a normal rate. [27-29] The reasoning evolved as it became clear that the true problem lay within cholinesterase enzyme activity and abnormalities, and not levels.
However, in certain clinical states such as pregnancy and liver disease, low levels of normal enzyme too could result in a prolonged block from succinylcholine.

Myalgia in patients following the administration of another neuromuscular blocker, decamethonium, prompted investigations into the possibility of myalgia following succinylcholine use in patients. This side effect was briefly mentioned in Bourne’s 1952 publication, where it was stated that patients who experienced vigorous fasciculations were more likely to experience postoperative muscle stiffness. [25] In 1954, Churchill-Davidson conducted a trial comparing the rates of muscle pain between patients who received succinylcholine for outpatient procedures versus inpatient procedures (i.e. confined to the hospital for at least 48 hours postoperatively). [30] For the outpatient group, 66% of patients reported generalized myalgias and stiffness starting postoperative day one. Only 14% of patients in the inpatient procedures group reported myalgia one day after their procedures. Churchill-Davidson attributed the difference in the rate of myalgia to the fact that the inpatient group was confined to bedrest after succinylcholine use. This report initially didn’t receive much attention but studies followed in 1956 and 1957 that reported incidences of postoperative muscle pains from 20 to 70% associated with succinylcholine. [31, 32] Numerous trials were conducted through the next decades to determine what pharmaceutical agents can help prevent the development of myalgia, a side effect that ranged from being a mild nuisance to temporarily debilitating for some patients. A meta-analysis of 52 studies by Schreiber et al in 2005 concluded that nonsteroidal anti-inflammatory drugs (NSAIDs), rocuronium, and lidocaine were most effective at preventing myalgia. [33] The meta-analysis also could not establish a correlation between the incidence of fasciculations and myalgia, suggesting that they are caused by different mechanisms, and thus an agent that prevents fasciculations may not necessarily prevent myalgia.
Animal studies conducted in 1960 showed that administration of succinylcholine produced a transient increase in plasma potassium, which might have been one of the earliest warnings of hyperkalemia caused by succinylcholine. [34] Though earlier studies identified the contraindication of succinylcholine in burn patients, which usually resulted in cardiac arrest, the mechanism underlying this side effect was undetermined. [35, 36] In 1969, Schaner and colleagues performed a series of studies showing that the injection of succinylcholine in burn patients, between 20-60 days post-burn, produced hyperkalemia; hyperkalemia increases with larger burns and larger doses of succinylcholine and the authors cautioned its use in burn patients. [37] In 1973, animal studies demonstrated that denervated muscle, found in burn and trauma victims, underwent massive depolarization in response to succinylcholine, which increases membrane permeability to potassium, thus contributing to hyperkalemia. [38]

Another side effect associated with succinylcholine, malignant hyperthermia, began to appear in the literature in the late 1960s. In 1966, cases of malignant hyperthermia were described in Canada and a warning sign for this side effect was the unexplained muscle rigidity that followed succinylcholine administration, especially when combined with halothane. [39, 40] More reports followed from Britain, describing similar problems with elevated temperature following anesthesia but maintained that the cause was not entirely due to succinylcholine. [41] Numerous trials began, aiming to find the etiology of malignant hyperthermia. Denborough and colleagues determined that muscle rigidity was due to an increase in free intracellular calcium ions, precipitated by an anesthetic agent, and this resulted in persistent muscle contracture with a concomitant increase in energy utilization and excess heat production. [42] A breakthrough animal study in 1991 revealed that malignant hyperthermia was correlated with a mutation in the skeletal muscle ryanodine receptor (RyR1). [43]
Minor side effects such as fasciculations and myalgia were reported in the early editions of anesthesia textbooks. [44-46] The earliest major side effect reported was prolonged apnea; this appeared in textbooks by 1955, three years after initial case reports. [44, 46, 47] Bradycardia was mentioned in textbooks starting in 1960, hyperkalemia was discussed starting in 1965, and malignant hyperthermia appeared starting in 1970; all lagging a few years behind the original case reports since textbooks were only updated every few years. [46, 48-52] Other minor side effects were included as textbooks continued to update into the 1970s; these included increased intraocular pressure, a small amount of histamine release, a weal and flare production similar to that produced by d-tubocurarine administration, tachycardia and other cardiac irregularities, hypertension, and cardiovascular collapse.

Succinylcholine was marketed as “Anectine” by BW Co. Its booklets included precautions, contraindications, and warnings as early as 1952-1956 (estimated) about prolonged apnea due to plasma-cholinesterase activity, muscle stimulation, and increased intraocular pressure that cautions use in intraocular surgery. (Figures 1-3) BW Co.’s 1952 Anectine booklet’s “Contraindications and Precautions” section warns against fasciculations and prolonged apnea. (Figure 1) Another Anectine booklet from 1954 includes a “Side Effects” section, which describes fasciculations as the only significant side effect. (Figure 2) A double-sided booklet insert from 1955 describes fasciculations as a side effect but otherwise notes that succinylcholine has “no toxic side effects”, though it is unclear if the lack of side effects included on this advertisement is due to text constraints or a deliberate marketing decision. Single-paged advertisements in journals such as Anesthesiology and Anesthesia & Analgesia boasted succinylcholine’s rapid acting properties but did not list side effects. (Figures 4-5) BW Co.’s own updated booklet in 1962 emphasized that succinylcholine had “virtually no toxicity;
virtually no side effects” in the beginning of the packet before listing prolonged apnea, fasciculations, and increased intraocular pressure under its “Contraindications and Precautions” section. (Figure 6) These warnings of adverse effects remained in other promotional material and only increased in number and detail. BW Co.’s 1975 booklet about Anectine included warnings about bradycardia, myalgia, malignant hyperthermia and hyperkalemia. (Figure 7) These side effects were not listed in the 1965 versions of the promotional material. Table 1 lists the appearance of complications in journals, textbooks in anesthesiology, and drug package inserts.

Documents submitted to the FDA from 1971 to 1973 by BW Co. provided some details pertaining to sterility and potency problems of the original packaging and reflected new information about toxicity. (Figure 8) The company also delayed sending current manufacturing information, prompting several reminders from the FDA. The application was initially marked incomplete since BW Co. did not include full reports of adequate Limulus Amebocyte Lysate testing, an endotoxin test required of all pharmaceuticals and devices that come in contact with blood of cerebrospinal fluid. The package insert updates were approved in December 1975, which included warnings of malignant hyperthermia and hyperkalemia in burn patients. (Figure 9) Other FDA documents noted that the resubmission of these applications “has been lengthy” and mostly due to insufficient data provided by the manufacturer. These documents point out that the company had been marketing succinylcholine (Flo-Pack) without an approved supplement for sterilization, and there was no specific mention about the suppression of known side effects. In 1981, during another package insert revision, the FDA made amendments to several sections, including the expansion of succinylcholine’s list of contraindications and required an entire section devoted to malignant hyperthermia. These warnings remained on the package inserts, which continue to be revised and resubmitted as late as 2010.
Discussion

D-tubocurarine enjoyed a short period of popularity before case reports suggested several side effects related to histamine release – hypotension, bradycardia, bronchospasm, and increased salivary secretions. Updated textbook editions reflected these details, but advertisements and promotional materials were slow to include these side effects. It is unclear whether this was due to limitations in the size of the advertisement, or if the manufacturers did not include negative effects.

Efforts to replace d-tubocurarine may have resulted in the development of succinylcholine. Scientists set out to synthesize a new anesthetic that mimicked the structure of d-tubocurarine. One of these compounds was decamethonium and it was theorized that its success was due to a 10-atom distance between its two nitrogen atoms. Succinylcholine, once called diacetycholine, was synthesized with the same goal of a 10-atom distance between its nitrogen atoms, and its structure resembled two acetylcholine molecules laid end to end, giving it depolarizing neuromuscular blocking properties. Succinylcholine became a very popular choice of muscle relaxant due to its rapid onset and short duration as a result of its rapid breakdown in the body. It replaced d-tubocurarine as the relaxant of choice for tracheal intubation and short surgical procedures. D-tubocurarine continued to be used for longer operations.

The regulations surrounding drug development and marketing evolved during the same time succinylcholine was synthesized and manufactured. Succinylcholine was manufactured and marketed with a clear purpose on its labels, and with instruction to be used by medical professionals only. In compliance with the voluntary program to report drug reactions, researchers documented any side effect they thought were attributed to succinylcholine use in
their case reports. Following the Kefauver-Harris Amendments of 1962, reports continued to be published of new side effects despite succinylcholine’s widespread market penetration by then. We found that BW Co. updated their packaging and marketing material to reflect new side effects and warnings, in line with the Fair Packaging and Labeling Act of 1966 and we found evidence the form of FDA documents of BW Co. updating their drug package inserts in 1970. Though it appears that BW Co. was slow at providing the required documents to the FDA and delayed the application, the manufacturer was compliant in updating its marketing and packaging material with new side effects in an appropriate manner.

Despite its shortcomings and well-documented side effects in promotional materials and package inserts, succinylcholine survives to this day in the U.S., unlike halothane and d-tubocurarine. Anesthesiologists still prefer its quick onset and short duration properties. Not surprisingly, this has prompted a search for new compounds that have the same action as succinylcholine without the side effects. Although newer agents may possess the ability to provide muscle relaxation quite rapidly, they suffer from prolonged duration of blockade. A recent development has been the introduction of a reversal agent sugammadex. This drug binds to steroid neuromuscular blockers such as rocuronium and vecuronium and inactivates them rapidly. Thus, in a roundabout manner, two agents administered in series can deliver the advantages offered by succinylcholine. A clinical trial compared the recovery time of rocuronium and sugammadex (to reverse the neuromuscular block) to succinylcholine; and found that of the rocuronium/sugammadex combination was shorter. [53, 54] However, sugammadex too is associated with side effects, including rare anaphylactic reactions. [55] Thus, it remains to be seen if this combination will successfully replace this long-standing muscle relaxant. We can look forward to newer relaxants to replace succinylcholine.
Conclusions

Anesthetic medications are bound to the same lifecycle as any other medication or consumer product. Their introduction, built upon years and decades of investigative efforts, fulfilled a specific niche in anesthesia and the relatively unregulated medical market allowed easy dissemination of the product to clinicians and researchers. These medications enjoyed great popularity during their early years as clinicians were eager to try drugs with novel properties. With broader use, some effects of the drugs that were previously undetected appeared. Initial single reports are often insufficient to influence the majority opinion but as more cases are reported, particularly when those with lethal outcomes capture the spotlight, further investigations, updated with the constantly growing knowledge of the medical field, are warranted to look for toxicity. Often, researchers choose to abandon the drug at this stage and look for better alternatives, but succinylcholine had too many clinical advantages to abandon it. The manufacturer amended the package insert and advertisements to warn against contraindications and adverse effects. Textbooks and other authoritative sources on pharmaceuticals also updated each edition to reflect additional side effects. Typically, by this time, clinicians become wary of the undesired outcomes of even those drugs with unique properties and moved on to other options. So, new clinical guidelines for succinylcholine were issued. Replacement drugs were and are continuing to be developed; the next few decades could present a new clinically relevant depolarizing muscle relaxant.

It’s difficult to say whether or not there will one day be a drug that will stay in use forever. The lifecycle of a medication seems to indicate that we will discover and confirm the adverse effects of drugs once they have widespread use and then move on to a better alternative.
As long as there is a need to improve pharmacological agents, there will be a drive for new discoveries.
EndNote Generated References


Figure 1. BWC Anectine booklet, 1952 (estimated), pages 1 and 3

‘ANECTINE’
CHLORIDE

SUCCYNETHYLCHOLINE CHLORIDE
STERILE SOLUTION

CAUTION: Succinylcholine Chloride may produce respiratory depression as a result of general muscular paralysis. While respiratory depression is usually of very short duration following a single dose of the drug, or following cessation of continuous intravenous administration, there may on occasion be more prolonged respiratory depression requiring controlled respiration and the administration of oxygen. This drug should be used only by those skilled in the administration of controlled respiration and facilities for this procedure and for the administration of oxygen should always be immediately available. Neostigmine and other anticholinesterase, as well as Tensilon, do not antagonize the action of Succinylcholine, but on the contrary prolong its effect. They are therefore contraindicated as antidotes for Succinylcholine.

‘ANECTINE’ Chloride brand Succinylcholine Chloride is an ultra-short-acting skeletal muscle relaxant, that is, following intravenous injection of small doses (10 mg. to 20 mg.) the relaxation persists approximately three minutes. For prolonged relaxation ‘ANECTINE’ may be given by continuous intravenous drip. The degree of relaxation may be controlled by adjusting the rate of flow of the solution. Upon stopping the intravenous drip, spontaneous respiration ordinarily resumes within a minute and recovery is complete within 5 minutes. The quick return of spontaneous respiration is a definite advantage. Tachyphylaxis does not occur and cumulative action is not ordinarily seen.

CHEMICAL PROPERTIES
Succinylcholine chloride, also referred to as diacetylcholine chloride, is a white, odorless, crystalline substance which is readily soluble in water. Chemically it is succinic acid bis (β-dimethylaminoethyl) ester dimethylchloride, and its formula is as follows:

\[
\text{CH}_2\text{COOCH}_2\text{CH}_2\text{N(CH}_3\text{)}_2\text{Cl} \\
\text{CH}_2\text{COOCH}_2\text{CH}_2\text{N(CH}_3\text{)}_2\text{Cl}
\]

The ester linkage is rapidly hydrolyzed in alkaline solutions but is relatively stable in acid solutions. In order to promote stability, solutions should be kept under refrigeration. It appears that succinylcholine is rapidly hydrolyzed following its injection and that this accounts for its extremely short duration of action and the rapid recovery of normal muscle tone.

PHARMACOLOGICAL ACTION
‘ANECTINE’ causes muscular paralysis by producing a blockage of nervous transmission at the myoneural junction. This action was first reported by Bovet et al. 

Independent studies at The Wellcome Research Laboratories have been conducted on the synthesis and pharmacology of the drug. de Boer and his associates have found that doses as low as 0.05 mg./Kg. given intravenously to cats are effective in producing muscular relaxation, and that intravenous doses of 0.1 mg./Kg. or more produce prompt and complete muscular paralysis which is characterized by short duration of action and extremely rapid recovery. Repeated injections produce reproducible and predictable muscular paralysis, neither tachyphylaxis nor significant cumulative effects being seen. ‘ANECTINE’ exerts its action independently of the presence of either ‘Synactine’ brand Decamethonium Bromide or d-tubocurarine, but if given while either of these drugs is exerting its muscle relaxant effect, it would produce an added degree of muscular relaxation.

For the Medical Profession only
Short Procedures: The short duration of action of ‘Anectine’ Chloride (usually about 3 minutes following a single intravenous injection) makes it ideally suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopedic manipulations, short surgical procedures such as tonsillectomies, and electroshock therapy. The optimum intravenous dose for such purposes will vary among individuals, usually ranging from 10 to 30 mg. For this purpose an intravenous technique may be used, but generally it will be more convenient to administer a single intravenous injection. For the latter procedure the 10 cc. multiple-dose vial of ‘Anectine’ Chloride Injection containing 20 mg. per cc. should be used (see listing at end of circular).

NOTE: Succinylcholine is rapidly hydrolyzed by alkaline solutions and therefore loses potency rapidly if mixed with thiopental sodium (pentothal sodium). Such mixtures, if used at all, must be used immediately; however, separate injection of ‘ANECTINE’ is preferable. In order to promote stability ‘ANECTINE’ should be kept under refrigeration.

CONTRAINDICATIONS AND PRECAUTIONS

The drug should be used only by those skilled in the administration of controlled respiration and facilities for this procedure and for the administration of oxygen should always be immediately available.

‘ANECTINE’ is not an anesthetic agent and should not be regarded as a substitute for anesthesia.

Some anesthesiologists believe that rapid injection is responsible for the muscular twitching that is seen just prior to relaxation. These fasciculations may be due to the rate of injection of the drug, and may be minimized or avoided by giving the injection more slowly.23

While respiratory depression is usually of very short duration following a single dose of the drug, or following cessation of continuous intravenous administration, there may be on occasion, especially with excessive doses, more prolonged respiratory depression19,21 requiring controlled respiration and the administration of oxygen.

The duration of the effect of ‘ANECTINE’ may depend on plasma-cholinesterase activity.24,26,27 Patients with severe liver disease, severe anemia, severe malnutrition, and possibly those suffering from polyphosphatase inactivated poisoning may have a decreased plasma-cholinesterase activity which may intensify and prolong the action of ‘ANECTINE’, especially if large doses are used.29,29 In such cases, in addition to the usual measures of controlled respiration and administration of oxygen, it may be desirable to administer plasma or whole blood for the purpose of restoring cholinesterase activity.28

Neostigmine and other anticholinesterases, as well as Tensilon, do not antagonize the action of ‘ANECTINE’, but on the contrary prolong its effect. They are therefore contraindicated as antidotes for ‘ANECTINE’. Intravenous injections of procaine likewise may prolong and intensify the action of ‘ANECTINE’.

BIBLIOGRAPHY


Figure 2. BWC Anectine booklet, 1954 (estimated), cover and side effects section
SIDE EFFECTS

‘Anectine’ is remarkably free from side effects even when given in doses several times larger than those used clinically. Even large doses have no direct effect on the heart or central nervous system. Clinical doses do not affect transmission in the autonomic nervous system. The drug does not interfere with metabolism or liver function, for the products of its hydrolysis, namely, succinic acid and choline, are both naturally occurring metabolites.14,15

The only significant side effect of ‘Anectine’ is the transient initial muscle stimulation which precedes the relaxation. This action is most apparent when the injection is given rapidly; it is manifested as diffuse uncoordinated fasciculations of muscle bundles or groups. Twitchings may be observed 15 to 60 seconds after beginning the injection; they may last from 10 to 120 seconds; their disappearance marks the onset of relaxation. These preliminary fasciculations are usually infrequent and of negligible intensity if the injection is given slowly—a point to be remembered when ‘Anectine’ is to be given for manipulation of fractures and dislocations.

Figure 3. BWC Anectine booklet 1955 (estimated)
Figure 4. A 1955 advertisement in Anesthesiology

**ANNIE THESIOLOGY says:**

"Good gracious!  
...and now WE'RE moving  
JUNE THIRTIETH.

Remember, good folks,  
if you write the Journal  
office after that date  
our address will be  
3 PENN CENTER PLAZA."

now available here  
the original short-acting muscle relaxant

**SUXINYL**

Chloride  
(brand of Succinylcholine chloride)

Useful as an adjunct to surgical anesthesia, endoscopy, manipulative procedures and electroshock therapy.

SUXINYL Chloride® is available in 10 cc. multipurpose vials containing 30 mg. succinylcholine chloride per cc.

®Known abroad as Stecline

E. FOUGERA & COMPANY, INC.  75 Varick Street, New York 13, N. Y.
Figure 5. A 1957 advertisement in Anesthesia & Analgesia

**MUSCLE RELAXATION ≠ MUSCLE TONE**

controlled change in seconds with

‘ANECTINE’®

Chloride brand
SUCINYLCHOLINE CHLORIDE

For single intravenous injection

‘ANECTINE’ INJECTION
20 mg. in each cc.
Multiple-dose vials of 10 cc.
Ready for immediate use.
May be given once or repeatedly as required.

For continuous intravenous infusion

‘ANECTINE’ SOLUTION
50 mg. in each cc.
and
100 mg. in each cc.
Both strengths in ampuls of 10 cc.
Either solution to be diluted for preparation of intravenous drip.

BURROUGHS WELLCOME & CO. (U.S.A.) INC. Tuckahoe, N. Y.
Figure 6. A 1962 BWC Anectine booklet, pages 3-6

'ANECTINE'

offers these advantages

1. QUICK ACTION. The relaxing effect of 'Anectine' is apparent within 30-60 seconds after intravenous injection.

2. RAPID RECOVERY. 'Anectine' is rapidly hydrolyzed; a single intravenous injection produces relaxation of about 3 minutes duration, followed by rapid recovery.

3. VIRTUALLY NO TOXICITY. The end products of 'Anectine' hydrolysis are the normally-occurring metabolites, succinic acid and choline.

4. VIRTUALLY NO SIDE EFFECTS. 'Anectine' appears to have no physiologic action except at the myoneural junction. In therapeutic dosage it does not generally influence other areas of the autonomic nervous system, blood pressure, heart rate or blood picture.

5. CONTROLLABILITY. With 'Anectine', the degree and duration of muscle relaxation is readily controlled by varying the dosage and rate of administration.

CHEMICAL PROPERTIES
Succinylcholine Chloride, also referred to as diacetylcholine chloride, is a white, odorless, crystalline substance which is readily soluble in water. Chemically it is succinic acid bis (β-dimethyl-aminoethyl) ester dimethochloride, and its formula is as follows:

\[
\begin{align*}
\text{CH}_2\text{COOCH}_2\text{CH}_2\text{N(CH}_3)_3 \\
\text{CH}_2\text{COOCH}_2\text{CH}_2\text{N(CH}_3)_3 + 2 \text{Cl}^{-}
\end{align*}
\]

The ester linkage is rapidly hydrolyzed in alkaline solutions but is relatively stable in acid solutions. In order to promote stability, solutions should be kept under refrigeration. It appears that succinylcholine is rapidly hydrolyzed following its injection and that this accounts for its extremely short duration of action and the rapid recovery of normal muscle tone.
1 Gm. ‘Anectine’ (the contents of one 10 cc. ampul containing 100 mg. per cc. or of one ‘Flo-Pack’ unit containing 1 Gm.) to 1,000 or 500 cc., respectively, of sterile 5% glucose solution or sterile isotonic saline solution. The more dilute solution (0.1% or 1 mg. per cc.) is probably preferable from the standpoint of ease of control of rate of administration of the drug and, hence, of relaxation. This intravenous drip solution containing 1 mg. per cc. may be administered at a rate of from 0.5 mg. (0.5 cc.) to 10 mg. (10 cc.) per minute to obtain the desired amount of relaxation. The amount required per minute will depend upon the individual response as well as the degree of relaxation required. In the experience of Foldes the average rate is 2.5 mg. per minute. In the series reported by Little, Hampton and Grosskreutz an average dose of 4.3 mg. per minute was used. The 0.2% solution may be especially useful in those cases where it is desired to avoid overburdening the circulation with a large volume of fluid, e.g., cardiac cases. In any case, the rate of administration will be varied from time to time. The degree of relaxation can be regulated to the needs of the surgeon by adjusting the drip.

**NOTE:** Succinylcholine is rapidly hydrolyzed by alkaline solutions and therefore loses potency rapidly if mixed with thiopental sodium (pentothal sodium). Such mixtures, if used at all, must be used within a few minutes of preparation; however, separate injection of ‘Anectine’ is preferable. Succinylcholine chloride is quite stable when stored under refrigeration. On standing at room temperature potency gradually decreases. The higher the concentration of a solution of Succinylcholine Chloride the more rapid will be the loss of potency at a given temperature.

**CONTRAINDICATIONS AND PRECAUTIONS**

Succinylcholine Chloride may produce respiratory depression as a result of general muscular paralysis. While respiratory depression is usually of very short duration following a single dose of the drug, or following cessation of continuous intravenous administration, there may on occasion be more prolonged respiratory depression requiring adequate respiratory exchange by the administration of artificial respiration. The drug should be used only by those skilled in the administration of assisted or controlled respiration and facilities for this procedure and the administration of oxygen should always be immediately available. Neostigmine and other anticholinesterases, as well as edrophonium (Tensilon) do not generally antagonize the action of Succinylcholine but, on the contrary, prolong its effect. Intravenous injection of procaine likewise may prolong the action of Succinylcholine. On rare occasions, however, Succinylcholine may produce prolonged respiratory depression due to the development
of a dual block.\textsuperscript{8,9,26-31} Under these circumstances edrophonium may be administered in a small test dose. If improvement in spontaneous respiration occurs, additional small doses of edrophonium may result in rapid return of the spontaneous respiratory pattern.\textsuperscript{8-11} ‘Anectine’ brand Succinylcholine Chloride is an ultra-short-acting skeletal muscle relaxant; that is, following intravenous injection of small doses (10 mg. to 40 mg.) the relaxation persists approximately three minutes. For prolonged relaxation ‘Anectine’ may be given by continuous intravenous drip. The degree of relaxation may be controlled by adjusting the rate of flow of the solution. Upon stopping the intravenous drip, spontaneous respiration ordinarily resumes within a minute and recovery is complete within 5 minutes. The quick return of spontaneous respiration is a definite advantage. Tachyphylaxis does not occur and cumulative action is not ordinarily seen.

‘Anectine’ should be used only by those skilled in the administration of artificial respiration. Facilities for providing adequate ventilation of the patient, including the administration of oxygen and the elimination of carbon dioxide, should always be immediately available. ‘Anectine’ is not an anesthetic agent and should not be regarded as a substitute for anesthesia; its use does not take the place of giving an adequate amount of anesthetic agent.

Some anesthesiologists believe that rapid injection is responsible for the muscular twitching that is seen just prior to relaxation. These fasciculations may be due to the rate of injection of the drug, and may be minimized or avoided by giving the injection more slowly.\textsuperscript{15,32}

While respiratory depression is usually of very short duration following a single dose of the drug, or following cessation of continuous intravenous administration, there may on occasion, especially with excessive doses, be more prolonged respiratory depression\textsuperscript{12,14} requiring artificial ventilation of the patient.

The duration of the effect of ‘Anectine’ may in part depend on plasma-cholinesterase activity.\textsuperscript{33-35} Patients with severe liver disease, severe anemia, severe malnutrition, and possibly those suffering from polyphosphate insecticide poisoning may have a decreased plasma-cholinesterase activity which may intensify and prolong the action of ‘Anectine’, especially if large doses are used.\textsuperscript{36,37} In such cases, in addition to the usual measures, it may be desirable to administer plasma or whole blood for the purpose of restoring cholinesterase activity.\textsuperscript{36}

There is evidence that intraocular pressure is increased slightly following injection of ‘Anectine’.\textsuperscript{38} This effect is seen immediately after the injection and during the fasciculatory phase; it subsides as complete
paralysis supervenes; it appears to be the result of brief contraction of the extraocular muscles. This suggests that 'Anectine' should be used with caution, if at all, in intraocular surgery. The opinion is expressed that the effect is probably not sufficient to contraindicate the drug in general surgery or electroshock therapy for patients with glaucoma or in patients undergoing eye surgery under general anesthesia.\textsuperscript{39, 40}

**CLINICAL OBSERVATIONS**

As an aid to bronchoscopy, Reitman\textsuperscript{17} reports that "After experience with an initial series of 100 bronchoscopies, with curare as the relaxant, it was found that succinylcholine was much better and it has been used in a second series of 100 bronchoscopies. The new technique has also been adapted for use in other surgical procedures that require excellent relaxation for short periods of time. It provides safety and comfort for the patient, permits the surgeon or bronchoscopist to do much better work, and reduces the emotional strain on all concerned."

Santos and Sweet\textsuperscript{18} advocate the use of succinylcholine even for poor-risk patients undergoing thoracic surgery, on the basis of good results obtained with its use in 100 such patients. "Particular preference is given to succinylcholine, a depolarizing relaxant drug, because of its short duration of action, and its easy controllability of administration."

In obstetrics, the safety of succinylcholine was determined by Kvisselgaard and Moya\textsuperscript{19} in studies of varying dosages in full-term vaginal deliveries. "...the threshold dose necessary to permit the passage of barely detectable quantities into the fetal blood is in the region of 300 mg., i.e. 5 to 6 times the usual clinical dose. ... None of the infants appeared to be affected by the relaxant, irrespective of the dose and time interval between injection and delivery."

In pediatric surgery, Telford and Keats\textsuperscript{20} found that succinylcholine "allows ideal operating conditions for the surgeon even in the smallest patients, with minimal cardiac effects of anesthetic agents. ... within ten minutes from cessation of the succinylcholine drip, respiratory activity returned and by the time the operation was completed (or before) the children were moving, breathing spontaneously and adequately."
Figure 7. A 1975 BWC Anectine booklet, pages 7-9

**ANECTINE brand Succinylcholine Chloride**

muscles and the diaphragm. The drug has no direct effect on the myocardium. Initially a transient bradycardia accompanied by hypotension, arrhythmias and even a sinus arrest may occur during endotracheal intubation due to an increase in vagal tone. This is noted particularly in children and is more apparent with repetitive injections than following continuous intravenous drip administration. These effects are enhanced by cyclopropane and halothane and are inhibited by thiopental and atropine. Later the drug may cause tachycardia and hypotension as a result of an asphyxial pressor response and mild sympathetic ganglion stimulation.

Succinylcholine causes a slight, transient increase in intraocular pressure. The effect is seen immediately after its injection and during the fasciculation phase. It appears to be the result of brief contraction of the extraocular muscles. This suggests that the drug should not be used when open eye injury is present and should be used with caution, if at all, in intraocular surgery. The opinion is expressed that the effect is probably not sufficient to contraindicate the drug in general surgery or electroshock therapy for patients with glaucoma or in patients undergoing eye surgery under general anesthesia.

Succinylcholine has no direct effect on the uterus or other smooth muscles. The drug is highly ionized and has a low lipid solubility; therefore, it will not cross the placenta readily. Further, the enzymatic destruction of succinylcholine is an important factor in controlling the concentration gradient. Infants are relatively more resistant to depolarizing relaxants than adults.

Tachyphylaxis may occur after repeated doses of succinylcholine.

**NOTE:** On rare occasions when succinylcholine is given over a long period of time, the characteristic depolarization block of the myoneural junction changes to a non-depolarizing block resulting in prolonged respiratory depression or apnea similar to the blockage caused by tubocurarine. Under those circumstances small repeated doses of prostigmine may shorten the action of succinylcholine.

**INDICATIONS:** Succinylcholine chloride is indicated as an adjunct to anesthesia to induce skeletal muscle relaxation. It may be employed to reduce the intensity of muscle contractions of pharmacologically or electrically induced convulsions.

**CONTRAINDICATIONS:** Succinylcholine is contraindicated for persons with a known hypersensitivity to the drug.

**WARNINGS:**

**WARNING:** Succinylcholine should be used only by those skilled in the management of artificial respiration and only when facilities are instantly available for endotracheal intubation and for providing adequate ventilation of the patient, including the administration of oxygen under positive pressure and the elimination of carbon dioxide. The clinician must be prepared to assist or to control respiration.
Succinylcholine should not be mixed with short-acting barbiturates in the same syringe, or administered simultaneously during intravenous infusion through the same needle. Solutions of succinylcholine have an acid pH whereas those of barbiturates are alkaline in reaction. Depending upon the resultant pH of a mixture of solutions of these drugs, either free barbituric acid may be precipitated or succinylcholine hydrolyzed.

Usage in Pregnancy: The safe use of succinylcholine has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should not be used in women of childbearing potential and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the unknown hazards.

Precautions: Low levels of, or abnormal variants of plasma cholinesterase may be associated with prolonged respiratory depression or apnea following the use of succinylcholine. Low levels of plasma cholinesterase may occur in patients with severe liver disease or cirrhosis, severe anemia, malnutrition, severe dehydration, changes in body temperature, exposure to neurotoxic insecticides or those receiving antimalarial drugs. Succinylcholine should be administered with extreme care to such patients and dosage should be minimal. If low plasma cholinesterase activity is suspected, a small test dose of from 5 to 10 mg of succinylcholine may be administered, or relaxation may be produced by the cautious administration of a 0.1% solution of the drug by intravenous drip. Drugs which either inhibit plasma cholinesterase, such as neostigmine or phospholine iodide, or compete with succinylcholine for the enzyme, as does intravenous procaine, should not be given concurrently with succinylcholine.

Succinylcholine should be administered with great caution to patients with severe burns, those recovering from severe trauma, those suffering from electrolyte imbalance, those receiving quinidine, those who have been digitalized recently or who may have digitalis toxicity as serious cardiac arrhythmias or cardiac arrest may result. Great caution should be observed also in patients with pre-existing hyperkalemia or who are paraplegic, have suffered spinal neuraxis injury, or have degenerative or dystrophic neuromuscular disease, as such patients tend to become severely hyperkalemic when succinylcholine is given.

When succinylcholine is given over a prolonged period of time, the characteristic depolarization block of the myoneural junction may change to a non-depolarizing block which results in prolonged respiratory depression or apnea. Under such circumstances, small repeated doses of neostigmine may possibly act as an antagonist. A peripheral nerve stimulator (e.g. the Wellcome Peripheral Nerve Stimulator) may be used to ascertain the type of neuromuscular blockade. If a depolarization block is present both fast (tetanic) and slow (twitch) rates of nerve stimulation are well sustained, and post-tetanic facilitation is absent. If a non-depolarizing block is present there is post-tetanic facilitation and “fade” of successive stimuli on both fast (tetanic) and slow (twitch) rates of nerve stimulation.

Succinylcholine should be used with caution during ocular surgery and in patients with glaucoma. The drug should be employed with caution in patients with fractures or muscle spasm as the muscle fasciculations may cause additional trauma. Muscle fasciculations and hyperkalemia may be reduced by administering a small dose of a non-depolarizing relaxant. If other relaxants are to be used during the same procedure, the possibility of a synergistic or antagonistic effect should be considered.
During the past few years, reports have called attention to a fulminating syndrome, malignant hyperthermia, observed during anesthesia. Its etiology is not fully understood. Malignant hyperthermia occurs in genetically prone individuals of all ages and both sexes receiving potent anesthetics such as halothane, methoxyflurane, cyclopropane and diethyl ether. It appears to develop irrespective of the concomitant use of a muscle relaxant, but may be triggered by succinylcholine. Because of the seriousness of this syndrome and the need for early effective treatment of the patient, it is suggested that the continuous monitoring of the temperature will serve as an aid to the early recognition of malignant hyperthermia.

ADVERSE REACTIONS: Adverse reactions consist primarily of an extension of the drug’s pharmacological actions. Profound and prolonged muscle relaxation may occur, resulting in respiratory depression to the point of apnea. Hypersensitivity to the drug may exist in rare instances.

The following adverse reactions have been reported: bradycardia, tachycardia, hypertension, hypotension, arrhythmias, cardiac arrest, prolonged respiratory depression or apnea, hyperthermia, increased intraocular pressure, muscle fasciculation, postoperative muscle pain, myoglobinemia and excessive salivation.

DOSAGE AND ADMINISTRATION: The dosage of succinylcholine is essentially individualized and its administration should always be determined by the clinician after careful assessment of the patient.

To avoid distress to the patient, succinylcholine should be administered only after unconsciousness has been induced.

FOR SHORT SURGICAL PROCEDURES: The average dose for relaxation of short duration is 40 mg (2.0 cc) Anectine brand Succinylcholine Chloride Injection given intravenously. The optimum dose will vary among individuals and may vary from 20 to 80 mg for adults (1.0 to 4.0 cc). Following administration of doses in this range, relaxation develops in about 1 minute; maximum muscular paralysis may persist for about 2 minutes, after which recovery rapidly takes place within 8 to 10 minutes. However, very large doses may result in more prolonged apnea. An initial test dose of 10 mg (0.5 cc) may be used to determine the sensitivity of the patient and the individual recovery time from the drug.

FOR LONG SURGICAL PROCEDURES: The dosage of succinylcholine chloride administered by infusion depends upon the duration of the surgical procedure and the need for muscle relaxation. The average rate of administration for continuous intravenous infusion is 2.5 mg per minute for adult patients. Solutions containing from 0.1% to 0.2% (1 to 2 mg per cc) succinylcholine chloride have commonly been used for continuous intravenous drip. Solutions of 0.1% or 0.2% may conveniently be prepared by adding 1 g succinylcholine chloride (the contents of one Anectine brand Succinylcholine Chloride Sterile Powder Flo-Pack unit containing 1 g) respectively to 1,000 or 500 cc of sterile solution such as sterile 5% dextrose solution or sterile isotonic saline or lactate solution. The more dilute solution (0.1% or 1 mg per cc) is probably preferable from the standpoint of ease of control of the rate of administration of the drug and hence, of relaxation. This intravenous drip solution containing 1 mg per cc may be administered at a rate of from 0.5 mg (0.5 cc) to 10 mg (10 cc) per minute to
Figure 8. 1972 FDA document

Burroughs Wellcome Company
Attention: D. A. Knight
3330 Cornwallis Road
Research Triangle Park, North Carolina 27709

Gentlemen:

We acknowledge the receipt on October 16, 1972 of your communication dated October 11, 1972 regarding your supplemental new drug application of October 19, 1970 and February 2, 1971 submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Anectine (succinylcholine chloride) Injection.

The supplemental application provides for updating manufacturing information as required by Federal Register Notice of August 26, 1970.

We have completed our review of this supplemental application. However, before we are able to reach a final conclusion the following additional information is necessary:

Please submit information to assure the sterility of the multiple dose vials is maintained during the actual period of use of the vials. It is necessary that an analytical procedure for methylparaben be submitted to the Administration in order to confirm that the potency of the methylparaben does not decrease below the labeled quantity during the stability studies.

We have reservations concerning the stability data submitted for Anectine Injection over the 24 month storage period. We note that Anectine Injection Lot #2-P-165 is below the accepted potency of 1% of label amount of succinylcholine chloride after 24 months of storage at 10°C. Potency data should be reported as percent of label amount of anhydrous succinylcholine chloride.

Please submit the above information promptly.

Sincerely yours,

Elmer A. Gardner, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Scientific Evaluation
Bureau of Drugs
Figure 9. 1975 FDA document

ANECTINE® brand SUCINYLCHOLINE CHLORIDE

DESCRIPTION: Anectine brand Succinylcholine Chloride is an ultra short-acting depolarizing type muscle relaxant. Chemically it is a di-quaternary base consisting of the di-chloride salt of the di-choline ester of succinic acid. It is a white, odorless, slightly bitter powder and very soluble in water. The drug is unstable with alkaline solutions, but relatively stable in acid solutions depending upon the concentration of the solution and the storage temperature. While solutions of succinylcholine chloride are sterilized by autoclaving, they should, nevertheless, be stored under refrigeration to preserve their potency.

ACTIONS: Anectine brand Succinylcholine Chloride causes skeletal muscle paralysis by blocking neural transmission at the myoneural junction. It competes with acetylcholine for the cholinergic receptors of the motor end plate. Like acetylcholine, bond with these receptors produces a depolarization. Following an initial transient muscle contraction often visible as fasciculations, neuromuscular transmission then becomes inhibited and remains so as long as there is an adequate concentration of succinylcholine at the receptor sites. The neuromuscular block so achieved produces a flaccid paralysis of skeletal muscles. Succinylcholine is dissipated through the enzymatic action of pseudocholinesterase at such a rate that the effect of a single paralyzing dose of the drug generally disappears within 8 to 10 minutes. When a single effective dose of the drug is given intravenously, muscular relaxation occurs within a minute, persists for about 2 minutes and returns to normal within 8 to 10 minutes. If a paralyzing dose is given intramuscularly, the onset of action may be delayed for 2 to 3 minutes. When given by intravenous drip, a predetermined degree of muscular relaxation can be closely approximated by adjusting the rate of flow of the infusion.

An important difference between succinylcholine and tubocurarine is that the former is not generally antagonized by anticholinesterases. On the contrary, such drugs as physostigmine, neostigmine and proscine usually prolong the action of succinylcholine. This would support the theory that succinylcholine is hydrolyzed by cholinesterases and that interference with this enzyme action results in persistence of activity of the drug. Succinylcholine is rapidly hydrolyzed by pseudocholinesterase to succinylmonocholine (a weak non-depolarizing type of muscle relaxant), and then more slowly to the normal metabolites succinic acid and choline. However, about 10% of the drug is excreted unchanged in the urine. The drug's action may be additionally altered by acetylcholine, dehydration, hypoamia, electrolyte imbalance, certain antibiotics, some carcinomas, procaine type local anesthetics or the administration of other non-depolarizing or depolarizing muscle relaxants.

The drug has no known effect on consciousness, the pain threshold or cerebration. It should, therefore, be used only during adequate anesthesia.

The paralysis following the administration of succinylcholine is generally initially selective and usually appears in the following muscles consecutively: levator muscles of the eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis and finally intercostal muscles and the diaphragm. The drug has no direct effect on the myocardium. Initially a transient bradycardia accompanied by hypotension, arrhythmias and even a sinus arrest may occur during endotracheal intubation due to an increase in vagal tone. This is noted particularly in children and is more apparent with repetitive injections than following continuous intravenous drip administration. These effects are enhanced by cyclopropane and halothane and are inhibited by thiopental and atroline. Later the drug may cause tachycardia and hypertension as a result of an asphyxial pressor response and mild sympathetic ganglion stimulation.
Succinylcholine causes a slight, transient increase in intracranial pressure. The effect is seen immedi-
ately after its injection and during the fasciculation phase. It appears to be the result of brief con-
traction of the extracranial muscles. This suggests that the drug should not be used when open
eye injury is present and should be used with caution, if at all, in intracranial surgery. The opinion
is expressed that the effect is probably not sufficient to contraindicate the drug in general surgery
or electroencephalography for patients with glaucoma or in patients undergoing eye surgery under
general anesthesia.

Succinylcholine has no direct effect on the uterus or other smooth muscles. The drug is highly
ionized and has a low lipid solubility; therefore, it will not cross the placenta readily. Further, the
enzymatic destruction of succinylcholine is an important factor in controlling the concentration.
Infants are relatively more resistant to depolarizing relaxants than adults.

Tetanyphaxis may occur after repeated doses of succinylcholine.

NOTE: In rare cases, when succinylcholine is given over a long period of time, the characteristic
depolarization block of the motor end junction changes to a non-depolarizing block resulting in pro-
genous respiratory depression or apnea; a similar effect is observed by intravenous. Under these
circumstances, the repeated administration of succinylcholine may shorten the action of succinylcholine.

INDICATIONS: Succinylcholine chloride is indicated as an adjunct to anesthesia to induce skeletal
muscle relaxation. It may be employed to reduce the intensity of muscle contractions of pharmacologic or electrically induced convulsions.

CONTRAINDICATIONS: Succinylcholine is contraindicated for persons with a known hypersensitivity to the drug.

WARNING: Succinylcholine should be used only by those skilled in the management of artificial respiration and only when facilities are immediately available for endotracheal intubation and for providing adequate respiration to the pa-
tient, including the administration of oxygen under positive pressure and the administration of carbon dioxide. The physician must be prepared to assist or to take over respiration.

Succinylcholine should not be mixed with short-acting barbiturates in the same syringe, or admis-
ted simultaneously during intravenous infusion through the same needle. Solutions of succinyl-
choline have an acid pH whereas those of barbiturates are alkaline in reaction. Depending upon the resultant pH of a mixture of these drugs, either free barbiturate or succinylcholine hydrochloride may be administered.

Usage in Pregnancy: The safe use of succinylcholine has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should not be used in women of child-
bearing potential and particularly during pregnancy unless in the judgment of the physician the potential benefits outweigh the unknown hazards.

PRECAUTIONS: Low levels of, or abnormal levels of plasma cholinesterase may be associated with prolonged respiratory depression of apnea following the use of succinylcholine. Low levels of plasma cholinesterase may occur in patients with severe liver disease or cirrhosis, severe anemia, malnutri-
tion, severe dehydration, changes in body temperature, exposure to toxicologic inorganic or those receiving anticholinergic drugs. Succinylcholine should be administered with extreme care to such patients and dosage should be reduced. If the plasma cholinesterase activity is suspected, a small test dose of 5 to 10 mg of succinylcholine may be administered, or respiration may be pro-
duced by the cautious administration of 0.1% solution of succinylcholine. Drugs which inhibit plasma cholinesterase, such as neostigmine or physostigmine salicylate, or compete with succinylcholine for the enzyme, as does intravenous procaine, should not be given concur-
rently with succinylcholine.

Succinylcholine should be administered with great caution to patients with severe burns, those re-
covering from severe trauma, those suffering from electrolyte imbalance, those receiving sulindac, those who have been digitized recently or who may have digitalis toxicity or serious cardiac arrhythmias or cardiac arrest may result. Great caution should be observed also in patients with

pre-existing hyperkalemia or who are paralytic, have suffered spinal neuraxis injury, or have de-
generative or dystrophic neuromuscular disease, as such patients tend to become severely hyper-
kaemic when succinylcholine is given.

When succinylcholine is given over a prolonged period of time, the characteristic depolarization
block of the motor end junction may change to a non-depolarizing block which results in prolonged
respiratory depression or apneic. Under such circumstances, small repeated doses of succinyl-
choline may possibly act as an antagonist. A peripheral nerve stimulator (for e.g. the Hume Peripheral
Nerve Stimulator) may be used to ascertain the type of neuromuscular blockade. If a depolarizing block
is present both fast twitch and slow twitch rates of nerve stimulation are well sustained, and post-
fasciculation facilitation is absent. If a non-depolarizing block is present there is post-fasciculation facili-
tation and "fade" of successive stimuli on both fast twitch and slow twitch rates of nerve stimula-
tion.

Succinylcholine should be used with caution during ocular surgery and in patients with glaucoma.
The drug should be employed with caution in patients with fractures or muscle spasm as the muscle
facilitations may cause additional trauma. Muscle fasciculations and hyperkalemia may be reduced
by administering a small dose of a non-depolarizing relaxant. If either relaxants are to be used during the
same procedure, the possibility of a synergistic or antagonistic effect should be considered.

During the past few years, reports have called attention to a fulminating syndrome, malignant hyper-
tension, observed during anesthesia. Its etiology is not clearly understood. Malignant hyperthermia
occurs genetically in patients of all ages and both sexes receiving patient anesthetics such as
thiamine, meperidine, fluphenazine, cyclopropane and diethyl ether. It appears to develop irrespective
of the concomitant use of a muscle relaxant, but may be triggered by succinylcholine. Because of the
seriousness of this syndrome and the need for early effective treatment of the patient, it is
suggested that the continuous monitoring of the temperature will serve as an aid to the early recog-
nition malignant hyperthermia.

ADVERSE REACTIONS: Adverse reactions consist primarily of an extension of the drug’s pharma-
cologic actions. Prolonged and prolonged muscle relaxation may occur, resulting in respiratory depression of the point of apnea. Hypersensitivity to the drug may also occur in rare instances.
The following adverse reactions have been reported: Bradycardia, tachycardia, hypertension, hypo-
tension, arrhythmias, cardiac arrest, prolonged respiratory depression or apnea, hyperventilation, in-
terrupted intracranial pressure, muscle fasciculations, postoperative muscle pain, myalgia and excessive salivation.

DOSAGE AND ADMINISTRATION: The dosage of succinylcholine is essentially individualized and its
administration should always be determined by the clinician after careful assessment of the patient.

To avoid distress to the patient, succinylcholine should be administered only after uncooperativeness has been induced.

FOR SHORT SURGICAL PROCEDURES: The average dose for relaxation of short duration is 40 mg
(2.0 cc) of the succinylcholine chloride (1 mg/cc). The drug is given intramuscularly. The optimal dose
will vary among individuals and may vary from 20 to 40 mg for adults (1.0 to 4.0 cc). Following ad-
ministration of doses in this range, relaxation develops in about 1 minute. Maximum muscular paral-
ysis may persist for about 2 minutes, after which recovery rapidly takes place within 5 to 10 min-
utes. However, very large doses may result in apnea prolongation. An initial test dose of 5 to 10 mg
(0.5 cc) may be used to determine the sensitivity of the patient and the individual recovery time from
the drug.

FOR LONG SURGICAL PROCEDURES: The dosage of succinylcholine chloride administered by infusion
depends upon the duration of the surgical procedure and the need for muscle relaxation. The average
rate of administration for continuous intravenous infusion is 2.5 mg per minute for adult patients.
Solutions containing 0.1% to 0.5% (1 mg to 2 mg per cc) succinylcholine chloride have con-
ventionally been used for continuous intravenous infusions. Solutions of 0.1% to 0.25% (0.5 mg to 1.25 mg per cc) may conventionally be prepared by adding 1 g succinylcholine chloride (the contents of 10 cc ampoule containing 100 mg per cc) or of one Atracurium succinylcholine chloroethane sterile powder Fo-Pack unit contain-
ing 1 g respectively to 1,000 or 500 ml of sterile solution such as sterile 5% dextrose solution or sterile isotonic saline or lactate solution. The more dilute solution (0.1% or 0.5 mg per cc) is prob-
ably preferable from the standpoint of ease of control of the rate of administration of the drug and
hence, of relaxation. This intravenous drip solution containing 1 mg per cc may be administered at

ACCEPTED MANUSCRIPT
Table 1. The year of appearance of select adverse effects of succinylcholine in journals, textbooks in anesthesiology, and drug package inserts.

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Year when adverse reaction appeared in literature</th>
<th>Year when adverse reaction appeared in different textbooks</th>
<th>Year when adverse reaction appeared in drug company literature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condition</td>
<td>Year(s)</td>
<td>References</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1956 – Hegarty P.</td>
<td>1961 – Dripps RD, Eckenhoff JE,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vandam LD. Introduction to Anesthesia. 2nd ed. Philadelphia: WB Saunders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Company; 1961.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Pharmacological Basis of Therapeutics. 2nd ed. New York: The Macmillan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Company; 1955.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1956 – Hegarty P.</td>
<td>1957 – Dripps RD, Eckenhoff JE,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vandam LD. Introduction to Anesthesia. 1st ed. Philadelphia: WB Saunders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Company; 1957.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1953 – Bourne, JG.</td>
<td>1960 – Wylie WD, Davidson HCC. A</td>
<td></td>
</tr>
<tr>
<td>Prolonged apnea</td>
<td>1952 – Bourne JG, Collier HO,</td>
<td>1961 – Dripps RD, Eckenhoff JE,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somers GF.</td>
<td>Vandam LD. Introduction to Anesthesia. 2nd ed. Philadelphia: WB Saunders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Company; 1961.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1953 – Bourne, JG.</td>
<td>1952 – Burroughs Wellcome and Company’s “Anectine” FDA document approval</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Anectine” booklet, “Precautions” section.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Changes in the blood</td>
<td>1975 – Burroughs Wellcome and Company’s “Anectine” FDA document approval</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1963 – McCaughey TJ.</td>
<td>1975 – Burroughs Wellcome and Company’s “Anectine” FDA document approval</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Burn Mortality and the</td>
<td>“Anectine” booklet, “Precautions” section.</td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Author</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>-----------</td>
<td></td>
</tr>
</tbody>
</table>

*In doses >30mg/kg (animal studies)*
<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>Year when adverse reaction appeared in literature</th>
<th>Year when adverse reaction appeared in different textbooks</th>
<th>Year when adverse reaction appeared in drug company literature</th>
</tr>
</thead>
</table>
1975 – Burroughs Wellcome and Company’s “Anectine” FDA document approval |
1975 – Burroughs Wellcome and Company’s “Anectine” FDA document approval |
<table>
<thead>
<tr>
<th>Year</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td>Author(s)</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
</tr>
</tbody>
</table>

*In doses >30mg/kg (animal studies)
Succinylcholine, a depolarizing neuromuscular blocker, was introduced into clinical practice in 1953.

It was associated with hyperkalemia and malignant hyperthermia.

These potential side effects were not known to the manufacturer when the drug was introduced.

We found no evidence that Burroughs Wellcome and Company, New York [the manufacturer] suppressed information about these side effects.

After several decades of clinical use, succinylcholine continues to be used throughout the world, although newer neuromuscular blockers and reversal agents may affect its popularity.